Related Experiment Videos
[Proton pump inhibitors in the treatment of reflux esophagitis]
1Service de gastro-entérologie CHU de Nancy-Brabois, Vandoeuvre-Lès-Nancy.
La Revue Du Praticien
|October 1, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Easy clip to treat anal fistula tracts: a word of caution.
International journal of colorectal disease·2015
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
Alimentary pharmacology & therapeutics·2005
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
Alimentary pharmacology & therapeutics·2004
[Helicobacter pylori eradication. Therapeutic evolution, value of complementary studies].
Presse medicale (Paris, France : 1983)·2001
[Evaluation of a new sequence of magnetic resonance cholangio-pancreatography in thick cut and one shot acquisition].
Gastroenterologie clinique et biologique·2000
[Alpha-gal syndrome, a new allergy that's causing a stir].
La Revue du praticien·2026
[Inflammation: effective response or vulnerability related to sex?]
La Revue du praticien·2026
[Ankylosing spondylitis is now termined as radiographic axial spondyloarthritis].
La Revue du praticien·2026
[Summary IgA nephropathy, or Berger's disease].
La Revue du praticien·2026
[Anti-VEGF treatment in age related macular degeneration].
La Revue du praticien·2026
[Producing evidence for all: geriatric oncology and the challenge of equity in health care].
La Revue du praticien·2026
Comparative drug survival of biologic classes in psoriasis: a Japanese single-centre cohort study.
European journal of dermatology : EJD·2026
Biologic treatments for palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis.
European journal of dermatology : EJD·2026
Safety and Efficacy of Doravirine/Islatravir (100 mg/0.25 mg) Once Daily after Islatravir Dose Reduction from 0.75 mg: Week 96 Results from an Open-Label Phase 3 Study in Adults with HIV-1.
Journal of acquired immune deficiency syndromes (1999)·2026
Target engagement and efficacy in disease-modifying trials of synuclein-related disorders.
Brain : a journal of neurology·2026